SCHEMBL526500

SCHEMBL526500

O=[N+]([O-])c1cccnc1S

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.56
POLB P06746 1/20 0.55
ALDH1A1 P00352 6/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
CYP2C19 P33261 1/20 0.50
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 5/20 0.46
LMNA P02545 4/20 0.46
GAA P10253 2/20 0.46
PAX8 Q06710 1/20 0.46
KDM4E B2RXH2 2/20 0.46
CTSB P07858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416795 1.00 PDE10A (0.56) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL8823975 0.98 PDE10A (0.55) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL15886186 0.79 PDE10A (0.39) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL6512953 0.78 PDE10A (0.60) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL29940575 0.78 PDE10A (0.60) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL29138695 0.77 PDE10A (0.50) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL244559 0.77 HSP90AA1 (0.59) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL29579675 0.77 PDE10A (0.58) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL294121 0.77 PDE10A (0.58) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL13093318 0.77 PDE10A (0.63) PDE10APOLBALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250146035-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-05-08 US claimed
US-12188069-B2 Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-01-07 US claimed
CN-111699248-B Biocatalysts and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds 密执安大学评议会 2024-05-24 CN claimed
EP-3746551-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS The Regents Of The University Of Michigan (US) 2020-12-09 EP claimed
US-20200370081-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-11-26 US claimed
CN-111699248-A Biocatalysts and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds 密执安大学评议会 2020-09-22 CN claimed
WO-2019152679-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-08 WO claimed
CN-106478749-B 2,3,4- triacetyl -1- (nitro -2- pyridyl group) sulfydryl-α-L- rock algae pyranoside 宁波大学 2019-04-16 CN claimed
EP-3262058-A1 A COMPOUND FOR PREPARING POLYPEPTIDES Universität Wien (AT) 2018-01-03 EP claimed
CN-106478749-A 2,3,4 triacetyl 1 (nitro 2 pyridine radicals) sulfydryl alpha L rock algae pyranosides and the synthesis of hydrolyzate 宁波大学 2017-03-08 CN claimed
WO-2016135071-A1 A COMPOUND FOR PREPARING POLYPEPTIDES Universität Wien (AT) 2016-09-01 WO claimed
EP-0152255-A2 New renin-inhibitory peptides and their use SANKYO COMPANY LIMITED (JP) 1985-08-21 EP claimed
JP-6228099-A None JP disclosed
US-12503422-B2 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor NEUROBO PHARMACEUTICALS, INC. (US) 2025-12-23 US disclosed
EP-4601685-A1 MODIFIED LONG PEPTIDES SUITABLE FOR USE IN IMMUNISATION Isabella Pharma B.V. (NL) 2025-08-20 EP disclosed
US-20250146035-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-05-08 US disclosed
EP-0089650-B1 PROCESS FOR PRODUCING ANTIFUNGAL PYRIDAZINONE DERIVATIVES AND CERTAIN NOVEL COMPOUNDS PRODUCED BY SUCH A PROCESS SANKYO COMPANY LIMITED (JP) 1986-12-30 EP disclosed
US-4603201-A Process for producing antifungal oyridazinone derivatives SANKYO COMPANY LIMITED (JP) 1986-07-29 US disclosed
EP-0152255-A2 New renin-inhibitory peptides and their use SANKYO COMPANY LIMITED (JP) 1985-08-21 EP disclosed
EP-0089650-A1 Process for producing antifungal pyridazinone derivatives and certain novel compounds produced by such a process SANKYO COMPANY LIMITED (JP) 1983-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250146035-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS CYP4F3, CYP2E1, CYP1A2 PDE10A 2837/4885POLB 3859/4885ALDH1A1 395/4885
US-12503422-B2 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor NPC1L1, NOTUM, CEL PDE10A 2356/4885POLB 626/4885ALDH1A1 1952/4885
US-20200370081-A1 BIOCATALYST AND METHODS FOR SYNTHESIZING MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS CYP4F3, CYP2E1, CYP1A2 PDE10A 2837/4885POLB 3859/4885ALDH1A1 395/4885
US-12188069-B2 Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds CYP4F3, CYP2E1, CYP1A2 PDE10A 2837/4885POLB 3859/4885ALDH1A1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.